Literature DB >> 35437325

LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation.

Creg J Workman1,2,3,4, Dario A A Vignali5,6,7,8,9, Clifford Guy10, Diana M Mitrea11,12, Po-Chien Chou10, Jamshid Temirov13, Kate M Vignali10,14,15, Xueyan Liu16,17, Hui Zhang16,18, Richard Kriwacki11,19, Marcel P Bruchez20,21,22, Simon C Watkins23.   

Abstract

LAG3 is an inhibitory receptor that is highly expressed on exhausted T cells. Although LAG3-targeting immunotherapeutics are currently in clinical trials, how LAG3 inhibits T cell function remains unclear. Here, we show that LAG3 moved to the immunological synapse and associated with the T cell receptor (TCR)-CD3 complex in CD4+ and CD8+ T cells, in the absence of binding to major histocompatibility complex class II-its canonical ligand. Mechanistically, a phylogenetically conserved, acidic, tandem glutamic acid-proline repeat in the LAG3 cytoplasmic tail lowered the pH at the immune synapse and caused dissociation of the tyrosine kinase Lck from the CD4 or CD8 co-receptor, which resulted in a loss of co-receptor-TCR signaling and limited T cell activation. These observations indicated that LAG3 functioned as a signal disruptor in a major histocompatibility complex class II-independent manner, and provide insight into the mechanism of action of LAG3-targeting immunotherapies.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35437325      PMCID: PMC9106921          DOI: 10.1038/s41590-022-01176-4

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   31.250


  45 in total

Review 1.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

2.  The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells.

Authors:  Creg J Workman; Dario A A Vignali
Journal:  Eur J Immunol       Date:  2003-04       Impact factor: 5.532

3.  Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

Authors:  Seng-Ryong Woo; Meghan E Turnis; Monica V Goldberg; Jaishree Bankoti; Mark Selby; Christopher J Nirschl; Matthew L Bettini; David M Gravano; Peter Vogel; Chih Long Liu; Stephanie Tangsombatvisit; Joseph F Grosso; George Netto; Matthew P Smeltzer; Alcides Chaux; Paul J Utz; Creg J Workman; Drew M Pardoll; Alan J Korman; Charles G Drake; Dario A A Vignali
Journal:  Cancer Res       Date:  2011-12-20       Impact factor: 12.701

Review 4.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

Authors:  Elisa Ruffo; Richard C Wu; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

5.  Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3.

Authors:  Creg J Workman; Kari J Dugger; Dario A A Vignali
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

6.  Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.

Authors:  B Huard; R Mastrangeli; P Prigent; D Bruniquel; S Donini; N El-Tayar; B Maigret; M Dréano; F Triebel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

7.  Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223).

Authors:  Creg J Workman; Dario A A Vignali
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

Review 8.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

9.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

Authors:  Shawn D Blackburn; Haina Shin; W Nicholas Haining; Tao Zou; Creg J Workman; Antonio Polley; Michael R Betts; Gordon J Freeman; Dario A A Vignali; E John Wherry
Journal:  Nat Immunol       Date:  2008-11-30       Impact factor: 25.606

Review 10.  LAG-3: from molecular functions to clinical applications.

Authors:  Takumi Maruhashi; Daisuke Sugiura; Il-Mi Okazaki; Taku Okazaki
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

View more
  2 in total

1.  LAG3 disrupts the TCR signal by local acidification.

Authors:  Claire Hivroz
Journal:  Nat Immunol       Date:  2022-05       Impact factor: 31.250

2.  LAG3 blockade coordinates with microwave ablation to promote CD8+ T cell-mediated anti-tumor immunity.

Authors:  Dong Shao; Yaping Chen; Hao Huang; Yingting Liu; Junjun Chen; Dawei Zhu; Xiao Zheng; Lujun Chen; Jingting Jiang
Journal:  J Transl Med       Date:  2022-09-30       Impact factor: 8.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.